SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on July 21, 2011. The registrant is incorporated in Colorado and maintains its principal executive offices in Castle Rock, CO. The filing addresses a corporate action taken to maintain compliance with NASDAQ listing requirements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance data.
Material Changes and Events
- Reverse Stock Split: The Company announced a reverse split of its common stock.
- Purpose: The action was taken specifically to maintain the Company's listing on the NASDAQ stock exchange.
- Reference: Details are contained in a press release dated July 19, 2011, filed as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of risks beyond the immediate necessity of the reverse split to avoid delisting. No unusual items or contingencies are disclosed in the text of this report.
Investor Verification Checklist
- Verify the specific ratio of the reverse stock split in the press release (Exhibit 99.1).
- Confirm the effective date of the reverse split and the new share count.
- Review the Company's current stock price relative to NASDAQ minimum bid price requirements.
- Check for any subsequent filings regarding the completion of the split.